JNK in spinal cord facilitates bone cancer pain in rats through modulation of CXCL1

Abstract

In patients with advanced cancer, cancer-induced bone pain (CIBP) is a severe and common problem that is difficult to manage and explain. As c-Jun N-terminal kinase (JNK) and chemokine (C-X-C motif) ligand 1 (CXCL1) have been shown to participate in several chronic pain processes, we investigated the role of JNK and CXCL1 in CIBP and the relationship between them. A rat bone cancer pain model was established by intramedullary injection of Walker 256 rat gland mammary carcinoma cells into the left tibia of Sprague-Dawley rats. As a result, intramedullary injection of Walker 256 carcinoma cells induced significant bone destruction and persistent pain. Both phosphorylated JNK1 (pJNK1) and pJNK2 showed time-dependent increases in the ipsilateral spinal cord from day 7 to day 18 after tumor injection. Inhibition of JNK activation by intrathecal administration of SP600125, a selective pJNK inhibitor, attenuated mechanical allodynia and heat hyperalgesia caused by tumor inoculation. Tumor cell inoculation also induced robust CXCL1 upregulation in the ipsilateral spinal cord on day 18 after tumor injection. Inhibition of CXCL1 by intrathecal administration of CXCL1 neutralizing antibody showed a stable analgesic effect. Intrathecal administration of SP600125 reduced CXCL1 increase in the spinal cord, whereas inhibition of CXCL1 in the spinal cord showed no influence on JNK activation. Taken together, these results suggested that JNK activation in spinal cord contributed to the maintenance of CIBP, which may act through modulation of CXCL1. Inhibition of the pJNK/CXCL1 pathway may provide a new choice for treatment of CIBP.

Keywords

bone cancer pain / c-Jun N-terminal kinase / chemokine (C-X-C motif) ligand 1 / SP600125 / neural-glial interaction

References

[1] Montiel-RuizRM, Acosta-GonzalezRI, Jimenez AndradeJM. Bone cancer pain: from preclinical pharmacology to clinical trials. Gac Med Mex, 2013, 149(2): 204-211 PMID: 23652187

[2] ZhangRX, LiuB, LiA, et al. . Interleukin 1beta facilitates bone cancer pain in rats by enhancing NMDA receptor NR-1 subunit phosphorylation. Neuroscience, 2008, 154(4): 1533-1538 PMCID: 2495055 PMID: 18554806

[3] CurrieGL, DelaneyA, BennettMI, et al. . Animal models of bone cancer pain: systematic review and meta-analyses. Pain, 2013, 154(6): 917-926 PMID: 23582155

[4] ShenW, HuXM, LiuYN, et al. . CXCL12 in astrocytes contributes to bone cancer pain through CXCR4-mediated neuronal sensitization and glial activation in rat spinal cord. J Neuroinflammation, 2014, 11(1): 1-14

[5] MantyhP. Bone cancer pain: causes, consequences, and therapeutic opportunities. Pain, 2013, 154(1): S54-S62 PMID: 23916671

[6] GaoYJ, JiRR. Activation of JNK pathway in persistent pain. Neurosci Lett, 2008, 437(3): 180-183 PMCID: 2486445 PMID: 18455869

[7] GaoYJ, ZhangL, SamadOA, et al. . JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci, 2009, 29(13): 4096-4108 PMCID: 2682921 PMID: 19339605

[8] GaoYJ, XuZZ, LiuYC, et al. . The c-Jun N-terminal kinase 1 (JNK1) in spinal astrocytes is required for the maintenance of bilateral mechanical allodynia under a persistent inflammatory pain condition. Pain, 2010, 148(2): 309-319 PMCID: 2814908 PMID: 20022176

[9] ZhuangZY, WenYR, ZhangDR, et al. . A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci, 2006, 26(13): 3551-3360 PMID: 16571763

[10] WangJG, StrongJA, XieW, et al. . The chemokine CXCL1/growth related oncogene increases sodium currents and neuronal excitability in small diameter sensory neurons. Mol Pain, 2008, 4(39): 1-15

[11] DongF, DuYR, XieW, et al. . Increased function of the TRPV1 channel in small sensory neurons after local inflammation or in vitro exposure to the proinflammatory cytokine GRO/KC. Neurosci Bull, 2012, 28(2): 155-164 PMCID: 3324197 PMID: 22466126

[12] YangRH, StrongJA, ZhangJM. NF-kappaB mediated enhancement of potassium currents by the chemokine CXCL1/growth related oncogene in small diameter rat sensory neurons. Mol Pain, 2009, 5: 26 PMCID: 2698898 PMID: 19476648

[13] QinX, WanY, WangX. CCL2 and CXCL1 trigger calcitonin gene-related peptide release by exciting primary nociceptive neurons. J Neurosci Res, 2005, 82(1): 51-62 PMID: 16047385

[14] ZhangZJ, CaoDL, ZhangX, et al. . Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons. Pain, 2013, 154(10): 2185-2197 PMCID: 3899784 PMID: 23831863

[15] MedhurstSJ, WalkerK, BowesM, et al. . A rat model of bone cancer pain. Pain, 2002, 96(1–2): 129-140 PMID: 11932069

[16] Mao-YingQL, ZhaoJ, DongZQ, et al. . A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells. Biochem Biophys Res Commun, 2006, 345(4): 1292-1298 PMID: 16725112

[17] WangXW, HuS, Mao-YingQL, et al. . Activation of c-jun N-terminal kinase in spinal cord contributes to breast cancer induced bone pain in rats. Mol Brain, 2012, 5: 21 PMCID: 3407760 PMID: 22681856

[18] GaoYJ, ChengJK, ZengQ, et al. . Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model. Exp Neurol, 2009, 219(1): 146-155 PMCID: 2728781 PMID: 19445931

[19] HargreavesK, DubnerR, BrownF, et al. . A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain, 1988, 32(1): 77-88 PMID: 3340425

[20] ZhouLJ, RenWJ, ZhongY, et al. . Limited BDNF contributes to the failure of injury to skin afferents to produce a neuropathic pain condition. Pain, 2010, 148(1): 148-157 PMID: 19945222

[21] HartungJE, CiszekBP, NackleyAG. beta2-and beta3-adrenergic receptors drive COMT-dependent pain by increasing production of nitric oxide and cytokines. Pain, 2014, 155(7): 1346-1355 PMID: 24727346

[22] BogoyevitchMA, KobeB. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev, 2006, 70(4): 1061-1095 PMCID: 1698509 PMID: 17158707

[23] WhiteFA, JungH, MillerRJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci USA, 2007, 104(51): 20 151-20 158

[24] ZhangJ, ShiXQ, EcheverryS, et al. . Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J Neurosci, 2007, 27(45): 12 396-12 406

[25] LiuYL, ZhouLJ, HuNW, et al. . Tumor necrosis factor-alpha induces long-term potentiation of C-fiber evoked field potentials in spinal dorsal horn in rats with nerve injury: the role of NF-kappa B, JNK and p38 MAPK. Neuropharmacology, 2007, 52(3): 708-715 PMID: 17084420

[26] McTigueDM, TaniM, KrivacicK, et al. . Selective chemokine mRNA accumulation in the rat spinal cord after contusion injury. J Neurosci Res, 1998, 53(3): 368-376 PMID: 9698165

[27] VallesA, Grijpink-OngeringL, de BreeFM, et al. . Differential regulation of the CXCR2 chemokine network in rat brain trauma: implications for neuroimmune interactions and neuronal survival. Neurobiol Dis, 2006, 22(2): 312-322 PMID: 16472549

[28] HorukR, MartinAW, WangZ, et al. . Expression of chemokine receptors by subsets of neurons in the central nervous system. J Immunol, 1997, 158(6): 2882-2890 PMID: 9058825

[29] NguyenD, StangelM. Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells. Brain Res Dev Brain Res, 2001, 28(1): 77-81

[30] OmariKM, JohnGR, SealfonSC, et al. . CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain, 2005, 128(5): 1003-1015 PMID: 15774504

[31] FilipovicR, JakovcevskiI, ZecevicN. GRO-alpha and CXCR2 in the human fetal brain and multiple sclerosis lesions. Dev Neurosci, 2003, 25(2–4): 279-290 PMID: 12966224

[32] PopivanovaBK, KoikeK, TonchevAB, et al. . Accumulation of microglial cells expressing ELR motif-positive CXC chemokines and their receptor CXCR2 in monkey hippocampus after ischemiareperfusion. Brain Res, 2003, 970(1–2): 195-204 PMID: 12706261

[33] XuJ, ZhuMD, ZhangX, et al. . NFkappaB-mediated CXCL1 production in spinal cord astrocytes contributes to the maintenance of bone cancer pain in mice. J Neuroinflammation, 2014, 11: 38 PMCID: 3941254 PMID: 24580964

[34] LoHM, LaiTH, LiCH, et al. . TNF-alpha induces CXCL1 chemokine expression and release in human vascular endothelial cells in vitro via two distinct signaling pathways. Acta Pharmacol Sin, 2014, 35(3): 339-350 PMCID: 4647895 PMID: 24487964